ライフサイエンスコーパス: letter

1 the issues have been addressed (see decision letter).

2 thy Study (ETDRS) letters (mean change, +0.6 letters).

3 17.7 ETDRS letters; monthly, 10.1-18.7 ETDRS letters).

4 ine to week 12 was +5.6 letters (range, 0-18 letters).

5 within 250 mum of foveal center if BCVA >=79 letters).

6 PRN, -1.6 ETDRS letters; monthly, -1.9 ETDRS letters).

7 The noninferiority margin was 3.5 letters.

8 heoretically cue them to point to particular letters.

9 an estimated gain of 0.37 approximate ETDRS letters.

10 tudy was powered to detect a difference of 8 letters.

11 Overall, 7.6% lost 15 or more letters.

12 ich is within the noninferiority margin of 4 letters.

13 , exceeding the noninferiority margin of 3.5 letters.

14 better, and 20.0% improved 10 or more ETDRS letters.

15 sual acuity (BCVA) between 24 letters and 78 letters.

16 s who had no previous experience with Korean letters.

17 models evaluated predictors of loss of >=15 letters.

18 The noninferiority margin was 4 letters.

19 -VEGF injections, there was a mean gain of 1 letter (0.95 letter; 95% confidence interval [CI] for ch

20 kness (CST) reduction were, respectively, +1 letter (1.4 letters for aflibercept vs. 0.4 letter for r

21 which time the change in mean BCVA was +4.0 letters, -1.9 letters, and +0.9 letters in the monthly,

22 es with initial VA of 20/40 or better and +3 letters (10.6 vs. 7.6 letters; P < 0.01) and -46 mum (-1

23 ant negative predictor of 12-month VA (-5.21 letters/100 mum; 95% confidence interval [CI], -10.21 to

24 5% confidence interval [CI], -10.21 to -0.22 letters/100 mum; P = 0.041) when adjusting for baseline

25 etinopathy Study (ETDRS) letters, -2.3 ETDRS letters, +2.9 ETDRS letters, and +2.7 ETDRS letters in t

26 Treatment Diabetic Retinopathy Study (ETDRS) letters, -2.3 ETDRS letters, +2.9 ETDRS letters, and +2.

27 rs (range, 22-80 years), ETDRS BCVA was 56.7 letters (20/74 Snellen equivalent), and central macular

28 tters (SD 4.5) in the placebo group and 80.4 letters (4.6) in the eplerenone group, with an adjusted

29 ellen equivalent, 20/40), 66.1 letters, 64.7 letters, 63.2 letters, and 61.5 letters (Snellen equival

30 .0 letters (Snellen equivalent, 20/40), 66.1 letters, 64.7 letters, 63.2 letters, and 61.5 letters (S

31 n adjusted estimated mean difference of 1.73 letters (95% CI -1.12 to 4.57; p=0.24) at 12 months.

32 etters) in the ranibizumab group and of +1.6 letters (95% CI, -0.2 to 3.3 letters; P = 0.97) in the a

33 rs (95% CI, -1.5 to 2.0 letters) versus +1.0 letters (95% CI, -0.7 to 2.8 letters; P = 0.66).

34 ar, as was the adjusted mean VA change, +0.3 letters (95% CI, -1.5 to 2.0 letters) versus +1.0 letter

35 r relapsed) experienced a mean loss of -8.65 letters (95% CI, -11.5 to -5.84, P < 0.001).

36 37 eyes (12%) from Swiss subjects lost 14.9 letters (95% CI, -24 to -5.7; P < 0.001) with 35% achiev

37 A was 20/32 to 20/40, mean 5-year VA was 3.2 letters (95% CI, 1.4-5.0) better than baseline but 4.6 l

38 % CI, 9.3-14.5) better than baseline but 4.8 letters (95% CI, 2.5-7.0) worse than 2 years.

39 letters) for the ranibizumab group and +4.6 letters (95% CI, 2.7-6.6 letters) for the aflibercept gr

40 n = 18) in treatment-naive patients and +4.9 letters (95% CI, 3-7; n = 19) in previously treated pati

41 5% CI, 1.4-5.0) better than baseline but 4.6 letters (95% CI, 3.1-6.1) worse than 2 years.

42 interval [CI], 5.9-9.0) but decreased by 4.7 letters (95% CI, 3.3-6.0) between 2 and 5 years.

43 s in which ME resolved gained a mean of 6.24 letters (95% CI, 4.40-8.09; P < 0.001) compared with eye

44 was 20/50 to 20/320, mean 5-year VA was 11.9 letters (95% CI, 9.3-14.5) better than baseline but 4.8

45 e in BCVA from baseline to month 24 was +6.6 letters (95% CI,4.7-8.5 letters) for the ranibizumab gro

46 The crude mean VA change of +1.5 letters (95% confidence interval [CI], 0-3.1 letters) in

47 bination OPT-302 with ranibizumab were +10.8 letters (95% confidence interval [CI], 4-17; n = 18) in

48 years, mean VA improved from baseline by 7.4 letters (95% confidence interval [CI], 5.9-9.0) but decr

49 ons, there was a mean gain of 1 letter (0.95 letter; 95% confidence interval [CI] for change in VA, +

50 rienced no gain in vision (mean change -1.30 letters; 95% CI, -2.70 to 0.09; P = 0.065), and eyes tha

51 an for as-needed treatment (difference, -2.4 letters; 95% CI, -4.8 to -0.1; P = 0.046).

52 was present (median BCVA, 71 letters vs. 74 letters), a finding supported by more advanced morpholog

53 e spelling errors, and visually fixated most letters about half a second before pointing to them.

54 Patients with AMD gained 4.7 logMAR letters after 12 months (P = 0.002), whereas PCV patient

55 70) letters, which improved by 9 (IQR, 1-14) letters after the first year of treatment (P < 0.001).

56 frequency that scaled in amplitude with both letter and offset size, starting near threshold.

57 he previously observed commonalities between letter and Vernier acuity may be due to common bottlenec

58 Letter and Vernier offset responses differed in both the

59 0.288]; per protocol [PP] population: +12.3 letters and +13.5 letters [P = 0.664]; respectively).

60 (intention-to-treat [ITT] population: +11.4 letters and +13.8 letters [P = 0.288]; per protocol [PP]

61 nd 517.7(201.79) mum; Group II: 60.2 (12.21) letters and 515.3 (198.37) mum].

62 CSFT) were comparable [Group I: 60.9 (13.10) letters and 517.7(201.79) mum; Group II: 60.2 (12.21) le

63 Baseline and 12-month VA were 52.8 +/- 20.9 letters and 65.9 +/- 17.3 letters (change, +13.1 +/- 20.

64 st-corrected visual acuity (BCVA) between 24 letters and 78 letters.

65 sual acuity+/-standard error of 77.9 +/- 1.4 letters and 81.3 +/- 0.4 letters, respectively (P = 0.02

66 visit before surgery, BCVA was 62.2 and 56.9 letters and CRT was 342 mum and 301 mum in the laser con

67 th treatment naive DMO with VA between 35-54 letters and CST of 400 um or more when aflibercept is us

68 current processes of reading, as elicited by letters and digits whose level of ambiguity was parametr

69 In Studies 1 and 2, we sent letters and emails with nudges designed to increase carp

70 More eyes with early DME gained 10 or more letters and fewer eyes lost 10 or more letters compared

71 including Bioorganic and Medicinal Chemistry Letters and the Journal of Medicinal Chemistry.

72 sured in many different ways, including with letters and Vernier offsets.

73 howed a lower mean VA (mean difference, -3.1 letters) and a thicker maculae (mean difference, +26 mum

74 Treatment Diabetic Retinopathy Study [ETDRS] letters), and central retinal thickness (CRT) from basel

75 e change in mean BCVA was +4.0 letters, -1.9 letters, and +0.9 letters in the monthly, monthly plus l

76 DRS) letters, -2.3 ETDRS letters, +2.9 ETDRS letters, and +2.7 ETDRS letters in the PDS 10-mg/ml, 40-

77 nt, 20/40), 66.1 letters, 64.7 letters, 63.2 letters, and 61.5 letters (Snellen equivalent, 20/60).

78 ding the ocher particles imbedded in the red letters, and at the submicrometric scale concentrated in

79 Mean VA at M01 was 63.2 letters, and CST was 299.7 mum.

80 acy with which they looked at and pointed to letters as they responded to novel questions.

81 ts (n = 13) gained a median of +45 and +57.5 letters at 6 and 12 months, respectively, and showed red

82 percent of patients gained 15 or more ETDRS letters at 6 months, increasing to 70.6% at 12 and 18 mo

83 13.8, 22.2 +/- 13.9 and 21.9 +/- 15.8 ETDRS letters at 6, 12 and 18 months, respectively.

84 an best-corrected visual acuity [BCVA], 48.2 letters at baseline) showed a higher incidence rate of f

85 e than eyes with occult CNV (mean BCVA, 57.9 letters at baseline; P < 0.01).

86 ications to nucleotides, logos with multiple letters at each position illustrate models with multi-nu

87 pandemic, 2014 Ebola outbreak, 2001 anthrax letter attacks, and 1984 Rajneeshee Salmonella attacks,

88 evealed that viewing a string activates this letter-based code in the lateral occipital (LO) region a

89 er VA; eyes 20/25 or better were a mean +1.9 letters better on ETDRS testing (P < 0.05) and eyes 20/1

90 ) and eyes 20/160 or worse were a mean +12.6 letters better on ETDRS testing (P < 0.05).

91 Overall, mean ETDRS BCVA was 6.1 letters better than Snellen VA (median, 5.8; 95% CI, 5.3

92 on eye, and 3 participants lost more than 15 letters by month 1.

93 but in its presence adopts the shape of the letter C ~20 nm across.

94 Absolute letter change and percentage of patients to achieve >=5

95 (adjusted change [aDelta]: 2.70 units per 5 letter change, P < 0.001), implant placement in at least

96 were 52.8 +/- 20.9 letters and 65.9 +/- 17.3 letters (change, +13.1 +/- 20.3 letters; P < 0.001).

97 One example is the relationship between letter chart acuity and reading ability, as demonstrated

98 more letters and fewer eyes lost 10 or more letters compared with eyes with late DME (47.4% vs. 33.9

99 onse had gained more than 5 additional ETDRS letters compared with those without DR ultra-response.

100 , mean change in BCVA from baseline was -5.9 letters correct (standard deviation, 13.0 letters correc

101 rs correct) in the intervention eye and -3.7 letters correct (standard deviation, 9.0 letters correct

102 3.7 letters correct (standard deviation, 9.0 letters correct) in the fellow eye.

103 .9 letters correct (standard deviation, 13.0 letters correct) in the intervention eye and -3.7 letter

104 Reductions in VA (aDelta: -0.014 per 5 letter decline, P = 0.003), infections requiring a presc

105 tral 1-mm diameter zone corresponded to 34.8 letters' decline in VA.

106 associated with poorer vision outcomes (0.02-letter decrease/day; P = 0.03; R(2) = 0.29).

107 This letter demonstrates that THC and VEA exist in the unvape

108 -matched controls participated in a one-back letter detection test while task-evoked pupillary respon

109 h an initially better BCVA at baseline (>=70 letters) did not demonstrate differences in BCVA or OCT

110 Stratification by CST SD demonstrated a 10-letter difference in 12-month VA between the first and f

111 This research letter discusses the association between label restricti

112 ssembly: 1) in an aptamer evolved from a six-letter DNA library to selectively bind liver cancer cell

113 e macaque monkeys passively viewed images of letters, English words and non-word strings, and tested

114 ided 90% confidence interval (CI) was -3.626 letters, exceeding the noninferiority margin of 3.5 lett

115 results from a large-scale, nationwide lost-letter experiment in which 5,980 letters were dispersed

116 response measured by fNIRS during an English letter fluency task is a promising biomarker for MDD.

117 odynamic response measured during an English letter fluency task.

118 letter (1.4 letters for aflibercept vs. 0.4 letter for ranibizumab; P = 0.4) and -30 mum (-85 vs. -5

119 reduction were, respectively, +1 letter (1.4 letters for aflibercept vs. 0.4 letter for ranibizumab;

120 of the minimum angle of resolution (logMAR) letters for AMD and PCV patients, respectively.

121 chieved significant visual improvement (10.4 letters for AMD, 17.1 letters for PCV with monotherapy,

122 andard deviation) improved, with 15.3+/-13.0 letters for bevacizumab and 15.5+/-13.3 letters for rani

123 count: +1.79 versus -0.95 approximate ETDRS letters for eyes receiving 7 or more injections versus f

124 1 letters for PCV with monotherapy, and 35.5 letters for PCV with combination therapy).

125 sual improvement (10.4 letters for AMD, 17.1 letters for PCV with monotherapy, and 35.5 letters for P

126 13.0 letters for bevacizumab and 15.5+/-13.3 letters for ranibizumab after 6 months of monthly treatm

127 andard-fluence group was 6.0 compared to 4.3 letters for the reduced-fluence group (p = 0.61).

128 umab group and +4.6 letters (95% CI, 2.7-6.6 letters) for the aflibercept group ( P = 0.15).

129 to month 24 was +6.6 letters (95% CI,4.7-8.5 letters) for the ranibizumab group and +4.6 letters (95%

130 mpleted 10 years of treatment dropped by 0.9 letters from baseline (95% confidence interval [CI], -4.

131 atment of Diabetic Retinopathy Study (ETDRS) letters from baseline at 6, 12 and 18 months.

132 Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline was achieved.

133 5 Early Treatment Diabetic Retinopathy Study letters from baseline, as well as first sustained absenc

134 s evaluated as change in mean number of BCVA letters from baseline, proportion of participants gainin

135 e of preinvitation, invitation, and reminder letters from their primary care practitioner offering pr

136 Here, we show how six-letter GACTZP DNA contributes this property in two parts

137 Mean letter gain at 12 months for the standard-fluence group

138 Treatment Diabetic Retinopathy Study (ETDRS) letter gain postoperatively.

139 f eyes, respectively, showed greater than 10-letter gain, whereas 13.2%, 14.7%, and 14.4% of eyes, re

140 There was a linear relationship between mean letters gained and mean number of injections, between 4

141 to first injection predicted less optimistic letter gains in unadjusted and adjusted models (P < 0.00

142 The original Letter has not been corrected online.

143 icipants with a worse BCVA at baseline (<=69 letters) improved by 6.7+/-7.0 letters with bevacizumab

144 mprovement from baseline of 15 or more ETDRS letters in BCVA at week 24.

145 arm, 47% of patients gained 15 or more ETDRS letters in BCVA versus 16% in the control arm (P < 0.001

146 rimary outcome was improvement of 15 or more letters in best-corrected visual acuity (BCVA) from base

147 in mean BCVA between treatment arms was 1.8 letters in favor of ranibizumab after 6 months of follow

148 baseline at Month 12 in BCVA was 6.7 (13.48) letters in Group I and 8.3 (13.53) letters in Group II a

149 7 (13.48) letters in Group I and 8.3 (13.53) letters in Group II and the change in CSFT was - 161.3 (

150 ths of follow-up; BCVA improved by 4.9+/-6.7 letters in the bevacizumab group and 6.7+/-8.7 letters i

151 of GA was 13.4 mm(2) and median BCVA was 43 letters in the intervention eye.

152 CVA was +4.0 letters, -1.9 letters, and +0.9 letters in the monthly, monthly plus laser, and PRN plus

153 IVT-AFL from baseline to 24 months was + 3.0 letters in the overall population (P < 0.05 vs baseline)

154 letters, +2.9 ETDRS letters, and +2.7 ETDRS letters in the PDS 10-mg/ml, 40-mg/ml, 100-mg/ml, and mo

155 tters in the bevacizumab group and 6.7+/-8.7 letters in the ranibizumab group.

156 6 Early Treatment Diabetic Retinopathy Study letters in treated eyes.

157 east moderate visual acuity loss (>=15 ETDRS letters) in eyes with IOI (7 in eyes with IOI + vasculit

158 letters (95% confidence interval [CI], 0-3.1 letters) in the ranibizumab group and of +1.6 letters (9

159 ndard error) changes in BCVA and LLVA (ETDRS letters) in the study eye from baseline to 24 months wer

160 In this Letter, in Fig. 3c and f the Saccharomyces cerevisiae an

161 mean change in visual acuity (VA [in logMAR letters]) in eyes that completed 10 years of treatment.

162 36 months, more FAi-treated eyes had a >=15-letter increase in BCVA from baseline and fewer FAi-trea

163 Treatment Diabetic Retinopathy Study (ETDRS) letters (interquartile range [IQR], 5.0-20.0) from 65.0

164 nge [IQR], 1.3-4.7), and median DVA was 58.0 letters (IQR, 34.0-73.0).

165 y, eyes with mild or moderate DR gained 10.0 letters (IQR, 5.0-22.0) from 65.0 (IQR, 58.0-76.0), eyes

166 R, 26.0-65.0), and eyes with PDR gained 15.0 letters (IQR, 6.0-29.5) from 55.0 (IQR, 35.0-61.0).

167 lost over time with a final VA change of +3 letters (IQR, 8-10 letters, P = 0.162).

168 8.0-76.0), eyes with severe NPDR gained 20.5 letters (IQR, 8.0-28.5) from 55.0 (IQR, 26.0-65.0), and

169 This letter is devoted to the application of machine learning

170 This letter is not about a single person, but the Black acade

171 refully read the recently published research letter "Is asthma protective of COVID-19?" by Carli et a

172 etinal fibrosis were the main reasons for 10 letter loss in the subset of eyes analyzed retrospective

173 f eyes, respectively, showed greater than 10-letter loss.

174 Interestingly, condolence letters may even increase prevalence of posttraumatic st

175 Treatment Diabetic Retinopathy Study (ETDRS) letters (mean change, +0.6 letters).

176 0.001), and 0.2 (95% CI: 0.02-0.4, P = 0.03) letters/month in cohorts 1, 2, and 3, respectively.

177 kers on average lost vision (PRN, -1.6 ETDRS letters; monthly, -1.9 ETDRS letters).

178 ion gains from baseline (PRN, 8.5-17.7 ETDRS letters; monthly, 10.1-18.7 ETDRS letters).

179 al acuity gain in nAMD was 7.4 +/- 2.2 ETDRS letters (n = 34; injection frequency: 7.4 +/- 0.4) respe

180 e presenting with baseline VA of 35-54 ETDRS letters (n = 43) had higher proportion of sub-optimal re

181 The earliest evoked responses to letters occurred on lateral occipital visual areas, pred

182 e have learned to communicate by pointing to letters of the alphabet.

183 tween intact and scrambled text comprised of letters of varying size.

184 analyzed per injection, 22.7% achieved a 15-letter or more improvement, and 37.8% achieved a 10-lett

185 or more improvement, and 37.8% achieved a 10-letter or more improvement.

186 of treatment-naive patients gained 10 or 15 letter or more in BCVA (P = 0.001 and P = 0.006, respect

187 , respectively) and baseline VA of 20 logMAR letters or fewer (adjusted odds ratio, 3.8 and 10.6 for

188 cted visual acuity (BCVA) letter score of 49 letters or more (>=1 GA lesion within 250 mum of foveal

189 incidence rate of first sustained gain of 15 letters or more decreased.

190 econdary outcomes included improvement of 10 letters or more in BCVA, change in central macular thick

191 No participants showed improvement of 15 letters or more in the intervention eye, and 3 participa

192 At 18 months, the percent of eyes losing 15 letters or more of BCVA was 22% (8 of 36) and 14% (5 of

193 incidence rate of first sustained gain of 15 letters or more than eyes with occult CNV (mean BCVA, 57

194 , proportion of participants gaining 15 BCVA letters or more, and growth rate of GA lesions at 12 mon

195 re was the change in visual acuity in logMAR letters over 12 months between the two groups analyzed w

196 ated a statistically significant gain of 3.6 letters over ranibizumab (P = 0.03).

197 nificantly improved by a mean of 18.4+/-21.4 letters (P < 0.0001), and central subfield thickness als

198 red with last visit before surgery) and 67.2 letters (P < 0.001 compared with last visit before surge

199 6 logMAR letters (P = 0.001) and 10.8 logMAR letters (P < 0.001) for monotherapy and combination ther

200 002), whereas PCV patients gained 6.6 logMAR letters (P = 0.001) and 10.8 logMAR letters (P < 0.001)

201 oth the laser control and IAI groups to 73.5 letters (P = 0.010 compared with last visit before surge

202 at [ITT] population: +11.4 letters and +13.8 letters [P = 0.288]; per protocol [PP] population: +12.3

203 col [PP] population: +12.3 letters and +13.5 letters [P = 0.664]; respectively).

204 aseline at Month 3 was 5.2 (12.2, [3.1, 7.3] letters, P < 0.0001) and at Month 12 was 3.4 (15.4, [0.2

205 01) and at Month 12 was 3.4 (15.4, [0.2-6.6] letters, P = 0.0352).

206 h a final VA change of +3 letters (IQR, 8-10 letters, P = 0.162).

207 terval [CI] for change in VA, +0.77 to +1.13 letter; P < 0.001).

208 5.9 +/- 17.3 letters (change, +13.1 +/- 20.3 letters; P < 0.001).

209 20/40 or better and +3 letters (10.6 vs. 7.6 letters; P < 0.01) and -46 mum (-148 vs. -102 mum; P < 0

210 abnormal baseline EZ (15.00 letters vs. 8.16 letters; P = 0.0005, with baseline BCVA, CST, and age as

211 s [SD, 8.1 letters] vs. 1.2 letters [SD, 5.3 letters; P = 0.04), a higher proportion with VA of 6/12

212 interval cohort without initial doses (- 2.5 letters; P = 0.365 vs baseline) at 24 months.

213 rs) versus +1.0 letters (95% CI, -0.7 to 2.8 letters; P = 0.66).

214 oup and of +1.6 letters (95% CI, -0.2 to 3.3 letters; P = 0.97) in the aflibercept group at 3 years i

215 Participants pointed to about one letter per second, rarely made spelling errors, and visu

216 ean BCVA decreased by approximately 1.5 to 2 letters per year.

217 4.3 (95% confidence interval [CI], 3.7-4.9) letters per year.

218 by measuring recognition accuracy of Korean letters presented in a flash to non-Korean subjects who

219 ge in BCVA from baseline to week 12 was +5.6 letters (range, 0-18 letters).

220 en equivalent, 20/800) and 70 or fewer ETDRS letters read (Snellen equivalent, 20/40) in the study ey

221 ary outcome was mean change in VA (number of letters read on a logarithm of the minimum angle of reso

222 Distance visual acuity (DVA) (letters read) in both eyes and treatments for nAMD admin

223 The primary outcome was BCVA, measured as letters read, at 12 months.

224 ly available SSD, the BrainPort, we compared letter recognition performance in three presentation mod

225 y mapping light perception, bar orientation, letter recognition, and Landolt C acuity.

226 CRVO patients (n = 39) gained a median of 20 letters relative to baseline at both 6 and 12 months and

227 This letter represents a consensus opinion of researchers stu

228 ror of 77.9 +/- 1.4 letters and 81.3 +/- 0.4 letters, respectively (P = 0.02).

229 cohorts with initial doses (+ 4.9 and + 4.0 letters, respectively; P < 0.05 vs baseline) and negativ

230 n a compositional manner by linearly summing letter responses.

231 The primary outcome was mean visual acuity letter score (range, 0-100; higher scores indicate bette

232 The main outcome was visual acuity letter score (VALS).

233 ver time showed that for BRVO patients, BCVA letter score increased by a mean of 24, from baseline of

234 at final visit; and for CRVO patients, BCVA letter score increased by a mean of 26, from baseline of

235 eye and best-corrected visual acuity (BCVA) letter score of 49 letters or more (>=1 GA lesion within

236 .001) in best-corrected visual acuity from a letter score of 63.38 (+/-7.92) at baseline to 76.38 (+/

237 in the primary outcome of mean visual acuity letter score over 24 weeks following initial treatment w

238 The mean visual acuity letter score over 24 weeks was 59.3 (Snellen equivalent,

239 The mean visual acuity letter score was 52.6 (Snellen equivalent, 20/100) in th

240 11] years; 115 [56%] men; mean visual acuity letter score, 34.5 [Snellen equivalent, 20/200]), 95% (1

241 atment Diabetic Retinopathy Study (appETDRS) letter score, was calculated using recorded Snellen visu

242 No difference in letter scores was observed between groups when the analy

243 7 Early Treatment Diabetic Retinopathy Study letter scores, respectively (P = 0.74).

244 Modelled mean BCVA at 12 months was 79.5 letters (SD 4.5) in the placebo group and 80.4 letters (

245 etters; Snellen equivalent, 20/160] vs. 71.8 letters (SD, 11.9 letters; Snellen equivalent, 20/40]; P

246 rs; Snellen equivalent, 20/500), versus 70.1 letters (SD, 12.8 letters; Snellen equivalent, 20/40) in

247 006), lower BCVA 2 years earlier (mean, 38.0 letters [SD, 26.7 letters; Snellen equivalent, 20/160] v

248 in VA (6.4 letters [SD, 8.1 letters] vs. 1.2 letters [SD, 5.3 letters; P = 0.04), a higher proportion

249 ated patients showed larger gains in VA (6.4 letters [SD, 8.1 letters] vs. 1.2 letters [SD, 5.3 lette

250 ely bind liver cancer cells; and 2) in a six-letter self-assembling GACTZP nanotrain that carries the

251 robotic behaviors, demonstrated by folding a letter shape "M," a dynamic gripper, and a dynamic pacma

252 urely visual model in which neurons tuned to letter shape respond to longer strings in a compositiona

253 stimulation enabled accurate recognition of letter shapes predicted by the brain's spatial map of th

254 st injection, mean refracted BCVAs were 68.0 letters (Snellen equivalent, 20/40), 66.1 letters, 64.7

255 etters, 64.7 letters, 63.2 letters, and 61.5 letters (Snellen equivalent, 20/60).

256 Mean baseline VA was 53.8 letters (Snellen equivalent, 20/80).

257 Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent, 20/800) and 70 or fewer ETD

258 patients with presenting VA of fewer than 35 letters (Snellen equivalent, 6/60) achieved significant

259 years earlier (mean, 38.0 letters [SD, 26.7 letters; Snellen equivalent, 20/160] vs. 71.8 letters (S

260 lent, 20/500), versus 70.1 letters (SD, 12.8 letters; Snellen equivalent, 20/40) in the other group.

261 uivalent, 20/160] vs. 71.8 letters (SD, 11.9 letters; Snellen equivalent, 20/40]; P < 0.0001), higher

262 14.9 letters (standard deviation [SD], 12.3 letters; Snellen equivalent, 20/500), versus 70.1 letter

263 Mean BCVA was 14.9 letters (standard deviation [SD], 12.3 letters; Snellen

264 We found that dissimilarities between letter strings in this model can explain human performan

265 The ability to recognize written letter strings is foundational to human reading, but the

266 es over early visual cortex, suggesting that letter structure is first extracted in second-tier extra

267 tworthiness were presented during a go/no-go letter target discrimination task synchronized with syst

268 puter screen (e.g., Find a red T among other letters that are either black or red.).

269 In the HTML version of this Letter, the affiliations for authors Andrew S.

270 Change history: In this Letter, the following text has been added to the Acknowl

271 atterns suggest that participants pointed to letters they selected themselves, not letters they were

272 ted to letters they selected themselves, not letters they were directed to by the assistant.

273 In his final letter to Nageli, Mendel proposed a Darwinian scenario f

274 25, 3193-3200; See also the response to this Letter to the Editor by Slette et al., 26, e1-e3.

275 luenced Mendel's classic 1866 paper, and his letters to Nageli.

276 VA change, +0.3 letters (95% CI, -1.5 to 2.0 letters) versus +1.0 letters (95% CI, -0.7 to 2.8 letter

277 e Early Treatment Diabetic Retinopathy Study letters, vision loss of more than 5 Early Treatment Diab

278 rs, the percentage of eyes with at least a 5-letter visual acuity decrease was 16% (33/205), 17% (36/

279 t and left eyes was present (median BCVA, 71 letters vs. 74 letters), a finding supported by more adv

280 than those with abnormal baseline EZ (15.00 letters vs. 8.16 letters; P = 0.0005, with baseline BCVA

281 wed larger gains in VA (6.4 letters [SD, 8.1 letters] vs. 1.2 letters [SD, 5.3 letters; P = 0.04), a

282 The proportion of patients gaining >=10 letters was significantly greater in the naive group, p

283 In this letter we report a diamond lateral FinFET fabricated usi

284 In this letter, we expand from a cylindrical geometry and invest

285 In this Letter, we present a solution to this issue, the so-call

286 To measure visual acuity for letters, we recorded evoked potentials to 3 Hz alternati

287 ponding proportions of eyes that gained >=15 letters were 12%, 19%, and 22%, respectively.

288 Confusion analyses showed that letters were confused based on their characteristics pre

289 onwide lost-letter experiment in which 5,980 letters were dispersed in a sample of 188 Italian commun

290 r follow-up, VA changes from baseline (ETDRS letters) were least squares means of +1.1 (95% confidenc

291 Treatment Diabetic Retinopathy Study [ETDRS] letters) were similar for 2012, 2013, and 2014 (53.6+/-2

292 VA was 60 (interquartile range [IQR], 45-70) letters, which improved by 9 (IQR, 1-14) letters after t

293 e 2-sided 90% confidence interval was -1.724 letters, which is within the noninferiority margin of 4

294 e plains-wanderer (Pedionomus torquatus) and letter-winged kite (Elanus scriptus), that suggest the e

295 gible patients who were sent an introductory letter with 14 days to opt out.

296 aseline (<=69 letters) improved by 6.7+/-7.0 letters with bevacizumab and 10.4+/-10.0 letters with ra

297 A gains from baseline were 5.8, 5.8, and 7.5 letters with LD combo, HD combo, and IAI, respectively (

298 7.0 letters with bevacizumab and 10.4+/-10.0 letters with ranibizumab, and central area thickness dec

299 d the entire central 1-mm diameter zone (2.7 letters/year vs. 2.8 letters/year; P = 0.94).

300 1-mm diameter zone (2.7 letters/year vs. 2.8 letters/year; P = 0.94).